Kiadis Pharma NV (XAMS:KDS) COGS-to-Revenue : 0.00 (As of Dec. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV COGS-to-Revenue?

Kiadis Pharma NV's Cost of Goods Sold for the six months ended in Dec. 2020 was €0.00 Mil. Its Revenue for the six months ended in Dec. 2020 was €17.50 Mil.

Kiadis Pharma NV's COGS to Revenue for the six months ended in Dec. 2020 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Kiadis Pharma NV's Gross Margin % for the six months ended in Dec. 2020 was N/A%.

Kiadis Pharma NV COGS-to-Revenue Historical Data

The historical data trend for Kiadis Pharma NV's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV COGS-to-Revenue Chart

Kiadis Pharma NV Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

COGS-to-Revenue

Get a 7-Day Free Trial

Kiadis Pharma NV Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20
COGS-to-Revenue	Get a 7-Day Free Trial											-	-	-	-	-

Kiadis Pharma NV COGS-to-Revenue Calculation

Kiadis Pharma NV's COGS to Revenue for the fiscal year that ended in Dec. 2020 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	17.5
	=	0.00

Kiadis Pharma NV's COGS to Revenue for the quarter that ended in Dec. 2020 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	17.5
	=	0.00

Kiadis Pharma NV (XAMS:KDS) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Kiadis Pharma NV's Gross Margin % for the six months ended in Dec. 2020 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 17.5
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Kiadis Pharma NV COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiadis Pharma NV (XAMS:KDS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (XAMS:KDS) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP

Website

https://www.kiadis.com

Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (XAMS:KDS) Headlines

No Headlines